Welcome to our dedicated page for Delivra Health Brands news (Ticker: $DHBUF), a resource for investors and traders seeking the latest updates and insights on Delivra Health Brands stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Delivra Health Brands's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Delivra Health Brands's position in the market.
Delivra Health Brands reported a 36% YoY revenue growth, achieving $8,792K in net revenue for the nine months ending March 31, 2024. The quarterly revenue rose by 31% to $3,071K. The company's adjusted EBITDA improved to $845K from $9K YoY. Gross profit for the nine months was $4,566K, a 61% increase, with a gross margin of 52%, up from 44%. However, total expenses increased by 22% to $3,973K due to marketing initiatives. Quarterly gross profit was $1,540K with a 50% margin. Net loss was $702K for the nine months, compared to $178K last year. The loss per share stood at $0.003 basic and $0.002 diluted. Overall, Delivra Health shows strong revenue growth and improved profitability, despite higher expenses.